Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results

Published: Mar 19, 2013

SEATTLE, March 18, 2013 -- /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012.

Back to news